This study examined the frequency of RUNX1 mutations in newly diagnosed patients with AML, and their effect on clinical outcomes and treatment response rates, including younger patients receiving chemotherapy and elderly patients receiving HMAs. Here, RUNX1 is linked to acute myeloid leukemia.